These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 23411006

  • 1. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T.
    J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
    [Abstract] [Full Text] [Related]

  • 2. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A, Ramírez-Morros AM, Pinó S, Gallego M, Jauregui-Amezaga A, Ricart E, Panés J.
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [Abstract] [Full Text] [Related]

  • 3. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
    Eder P, Katulska K, Krela-Kaźmierczak I, Stawczyk-Eder K, Klimczak K, Szymczak A, Linke K, Łykowska-Szuber L.
    Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ.
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [Abstract] [Full Text] [Related]

  • 6. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment.
    Naganuma M, Okuda S, Hisamatsu T, Matsuoka K, Mori K, Hosoe N, Nakazato Y, Ogata H, Kanai T.
    Abdom Radiol (NY); 2017 Jan; 42(1):141-151. PubMed ID: 27549100
    [Abstract] [Full Text] [Related]

  • 7. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W, Wang Y, Oddens BJ, Link R.
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 10. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives).
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [Abstract] [Full Text] [Related]

  • 11. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, Takatsu N, Ninomiya K, Tsurumi K, Sato Y, Takahashi H, Ookado Y, Koga A, Kinjo K, Nagahama T, Hisabe T, Takaki Y, Yao K.
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [Abstract] [Full Text] [Related]

  • 12. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases.
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 14. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW.
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [Abstract] [Full Text] [Related]

  • 15. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 16. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh A, Veres G.
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [Abstract] [Full Text] [Related]

  • 17. Magnetic Resonance enteroclysis imaging in Crohn's disease.
    Broglia L, Gigante P, Papi C, Ferrari R, Gili L, Capurso L, Castrucci M.
    Radiol Med; 2003 Aug; 106(1-2):28-35. PubMed ID: 12951548
    [Abstract] [Full Text] [Related]

  • 18. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [Abstract] [Full Text] [Related]

  • 19. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J.
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [Abstract] [Full Text] [Related]

  • 20. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
    Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G.
    J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.